Lipidoid nanoparticles containing PD-L1 siRNA delivered in vivo enter Kupffer cells and enhance NK and CD8+ T cell-mediated hepatic antiviral immunity

Molecular Therapy Nucleic Acids

Volumn 2, Issue , 2013, Pages e72-

  Dolina, Joseph S ^a   Sung, Sun Sang J ^a   Novobrantseva, Tatiana I ^b   Nguyen, Tuyen M ^b   Hahn, Young S ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b ALNYLAM PHARMACEUTICALS   (United States)

Author keywords

Lipidoid nanoparticles; NK cells; Nucleic acid therapeutics; PD L1; T cells

Indexed keywords

GAMMA INTERFERON; GRANZYME B; IMMUNOLOGIC AGENT; LIPIDOID NANOPARTICLE; NANOPARTICLE; PD 1 LIGAND; UNCLASSIFIED DRUG;

ADENOVIRUS INFECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOMEGALOVIRUS INFECTION; GENE SILENCING; IMMUNOTHERAPY; IN VIVO STUDY; KUPFFER CELL; MEMORY T LYMPHOCYTE; MOUSE; NANOENCAPSULATION; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; VIRAL CLEARANCE; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTION;

EID: 84878826070     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2012.63     Document Type: Article

References (50)

1. Tiegs, G and Lohse, AW (2010). Immune tolerance: what is unique about the liver. J Autoimmun 34: 1-6.
2. Rehermann, B and Nascimbeni, M (2005). Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 5: 215-229. (Pubitemid 40364823)
3. Neumann-Haefelin, C, Blum, HE, Chisari, FV and Thimme, R (2005). T cell response in hepatitis C virus infection. J Clin Virol 32: 75-85. (Pubitemid 40093957)
4. Callendret, B and Walker, C (2011). A siege of hepatitis: immune boost for viral hepatitis. Nat Med 17: 252-253.
5. Keir, ME, Freeman, GJ and Sharpe, AH (2007). PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues. J Immunol 179: 5064-5070.
6. Dong, H, Zhu, G, Tamada, K, Flies, DB, van Deursen, JM and Chen, L (2004). B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes. Immunity 20: 327-336. (Pubitemid 38388234)
7. Carter, L, Fouser, LA, Jussif, J, Fitz, L, Deng, B, Wood, CR et al. (2002). PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol 32: 634-643. (Pubitemid 34257540)
8. Benson, DM Jr, Bakan, CE, Mishra, A, Hofmeister, CC, Efebera, Y, Becknell, B et al. (2010). The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116: 2286-2294.
9. Barber, DL, Wherry, EJ, Masopust, D, Zhu, B, Allison, JP, Sharpe, AH et al. (2006). Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439: 682-687. (Pubitemid 43237609)
10. Alvarez, IB, Pasquinelli, V, Jurado, JO, Abbate, E, Musella, RM, de la Barrera, SS et al. (2010). Role played by the programmed death-1-programmed death ligand pathway during innate immunity against Mycobacterium tuberculosis. J Infect Dis 202: 524-532.
11. Ishida, Y, Agata, Y, Shibahara, K and Honjo, T (1992). Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11: 3887-3895.
12. Chen, Y, Wu, S, Guo, G, Fei, L, Guo, S, Yang, C et al. (2011). Programmed death (PD)-1- deficient mice are extremely sensitive to murine hepatitis virus strain-3 (MHV-3) infection. PLoS Pathog 7: e1001347.
13. Okazaki, T and Honjo, T (2007). PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 19: 813-824. (Pubitemid 47241890)
14. Okazaki, T and Honjo, T (2006). The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 27: 195-201.
15. Folkl, A and Bienzle, D (2010). Structure and function of programmed death (PD) molecules. Vet Immunol Immunopathol 134: 33-38.
16. Fife, BT, Pauken, KE, Eagar, TN, Obu, T, Wu, J, Tang, Q et al. (2009). Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol 10: 1185-1192.
17. Krueger, PD, Lassen, MG, Qiao, H and Hahn, YS (2011). Regulation of NK cell repertoire and function in the liver. Crit Rev Immunol 31: 43-52.
18. Narni-Mancinelli, E, Jaeger, BN, Bernat, C, Fenis, A, Kung, S, De Gassart, A et al. (2012). Tuning of natural killer cell reactivity by NKp46 and Helios calibrates T cell responses. Science 335: 344-348.
19. Loke, P and Allison, JP (2003). PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci USA 100: 5336-5341. (Pubitemid 36542706)
20. Iwai, Y, Terawaki, S, Ikegawa, M, Okazaki, T and Honjo, T (2003). PD-1 inhibits antiviral immunity at the effector phase in the liver. J Exp Med 198: 39-50. (Pubitemid 36870184)
21. Zou, W and Chen, L (2008). Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 8: 467-477. (Pubitemid 351733418)
22. Melero, I, Hervas-Stubbs, S, Glennie, M, Pardoll, DM and Chen, L (2007). Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 7: 95-106. (Pubitemid 46160986)
23. Fire, A, Xu, S, Montgomery, MK, Kostas, SA, Driver, SE and Mello, CC (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806-811. (Pubitemid 28099681)
24. Meade, BR and Dowdy, SF (2009). The road to therapeutic RNA interference (RNAi): Tackling the 800 pound siRNA delivery gorilla. Discov Med 8: 253-256.
25. Novina, CD and Sharp, PA (2004). The RNAi revolution. Nature 430: 161-164. (Pubitemid 38902417)
26. de Fougerolles, A, Vornlocher, HP, Maraganore, J and Lieberman, J (2007). Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 6: 443-453. (Pubitemid 47064567)
27. Hobo, W, Maas, F, Adisty, N, de Witte, T, Schaap, N, van der Voort, R et al. (2010). siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells. Blood 116: 4501-4511.
28. Bumcrot, D, Manoharan, M, Koteliansky, V and Sah, DW (2006). RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2: 711-719. (Pubitemid 44764213)
29. Love, KT, Mahon, KP, Levins, CG, Whitehead, KA, Querbes, W, Dorkin, JR et al. (2010). Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci USA 107: 1864-1869.
30. Novobrantseva, TI, Borodovsky, A, Wong, J, Klebanov, B, Zafari, M, Yucius, K et al. (2012). Systemic RNAi-mediated gene silencing in nonhuman primate and rodent myeloid cells. Mol Ther Nucleic Acids 1: e4.
31. Wahl, C, Bochtler, P, Chen, L, Schirmbeck, R and Reimann, J (2008). B7-H1 on hepatocytes facilitates priming of specific CD8 T cells but limits the specific recall of primed responses. Gastroenterology 135: 980-988.
32. Kassel, R, Cruise, MW, Iezzoni, JC, Taylor, NA, Pruett, TL and Hahn, YS (2009). Chronically inflamed livers up-regulate expression of inhibitory B7 family members. Hepatology 50: 1625-1637.
33. Wu, K, Kryczek, I, Chen, L, Zou, W and Welling, TH (2009). Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions. Cancer Res 69: 8067-8075.
34. Golden-Mason, L, Klarquist, J, Wahed, AS and Rosen, HR (2008). Cutting edge: programmed death-1 expression is increased on immunocytes in chronic hepatitis C virus and predicts failure of response to antiviral therapy: race-dependent differences. J Immunol 180: 3637-3641.
35. Lukens, JR, Cruise, MW, Lassen, MG and Hahn, YS (2008). Blockade of PD-1/B7-H1 interaction restores effector CD8+ T cell responses in a hepatitis C virus core murine model. J Immunol 180: 4875-4884.
36. Mueller, SN, Vanguri, VK, Ha, SJ, West, EE, Keir, ME, Glickman, JN et al. (2010). PDL1 has distinct functions in hematopoietic and nonhematopoietic cells in regulating T cell responses during chronic infection in mice. J Clin Invest 120: 2508-2515.
37. Wolfrum, C, Shi, S, Jayaprakash, KN, Jayaraman, M, Wang, G, Pandey, RK et al. (2007). Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 25: 1149-1157. (Pubitemid 47538115)
38. Gillard, GO, Bivas-Benita, M, Hovav, AH, Grandpre, LE, Panas, MW, Seaman, MS et al. (2011). Thy1+ NK [corrected] cells from vaccinia virus-primed mice confer protection against vaccinia virus challenge in the absence of adaptive lymphocytes. PLoS Pathog 7: e1002141.
39. Haeryfar, SM and Hoskin, DW (2004). Thy-1: more than a mouse pan-T cell marker. J Immunol 173: 3581-3588. (Pubitemid 39280715)
40. Alter, G and Altfeld, M (2011). Mutiny or scrutiny: NK cell modulation of DC function in HIV-1 infection. Trends Immunol 32: 219-224.
41. Liu, ZX, Govindarajan, S, Okamoto, S and Dennert, G (2000). NK cells cause liver injury and facilitate the induction of T cell-mediated immunity to a viral liver infection. J Immunol 164: 6480-6486. (Pubitemid 30408832)
42. Wiesel, M and Oxenius, A (2012). From crucial to negligible: functional CD8+ T-cell responses and their dependence on CD4+ T-cell help. Eur J Immunol 42: 1080-1088.
43. Wuensch, SA, Spahn, J and Crispe, IN (2010). Direct, help-independent priming of CD8+ T cells by adeno-associated virus-transduced hepatocytes. Hepatology 52: 1068-1077.
44. Leuschner, F, Dutta, P, Gorbatov, R, Novobrantseva, TI, Donahoe, JS, Courties, G et al. (2011). Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol 29: 1005-1010.
45. Cubillos-Ruiz, JR, Engle, X, Scarlett, UK, Martinez, D, Barber, A, Elgueta, R et al. (2009). Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J Clin Invest 119: 2231-2244.
46. Frank-Kamenetsky, M, Grefhorst, A, Anderson, NN, Racie, TS, Bramlage, B, Akinc, A et al. (2008). Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci USA 105: 11915-11920.
47. Lukens, JR, Dolina, JS, Kim, TS, Tacke, RS and Hahn, YS (2009). Liver is able to activate naïve CD8+ T cells with dysfunctional anti-viral activity in the murine system. PLoS ONE 4: e7619.
48. Lassen, MG, Lukens, JR, Dolina, JS, Brown, MG and Hahn, YS (2010). Intrahepatic IL-10 maintains NKG2A+Ly49- liver NK cells in a functionally hyporesponsive state. J Immunol 184: 2693-2701.
49. Ackerman, ME, Moldt, B, Wyatt, RT, Dugast, AS, McAndrew, E, Tsoukas, S et al. (2011). A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J Immunol Methods 366: 8-19.
50. McLean, IW and Nakane, PK (1974). Periodate-lysine-paraformaldehyde fixative. A new fixation for immunoelectron microscopy. J Histochem Cytochem 22: 1077-1083.